Sophiris Bio Inc. (NASDAQ:SPHS) saw strong trading volume on Friday . 4,610,476 shares traded hands during mid-day trading, an increase of 4% from the previous session’s volume of 4,421,246 shares.The stock last traded at $5.50 and had previously closed at $5.68.

A number of analysts have recently weighed in on the stock. Maxim Group upped their target price on shares of Sophiris Bio from $4.00 to $6.00 and gave the stock a “buy” rating in a research report on Wednesday, August 10th. Echelon Wealth Partners reaffirmed a “buy” rating and issued a $5.00 target price on shares of Sophiris Bio in a research report on Friday, June 10th.

The company’s 50 day moving average is $4.24 and its 200 day moving average is $2.20. The stock’s market cap is $120.52 million.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.